MAP2K1 and neoplasm: We expected that this improved PA variant, termed IC3-PA (Table S1, Supplementary Material), combined with our novel MEK1/2-specific LF variant (see below), would form a highly tumor-selective MEK inactivator for tumor targeting (Figure 1A).